RCTJadad 4/5RandomizedDouble-BlindPlacebo-Controlled

Creatine Loading and Sleep: What a New 7-Day Trial Really Shows (And Doesn't)

NutrientsDecember 7, 2025Vol. 17 (24)

Summary

If you already take creatine for the gym, this study gives you a bonus reason to keep it in your stack: it might help you feel like you slept better, too. Researchers ran a rigorous randomized, double-blind, placebo-controlled crossover trial — the "gold standard" design where every participant cycles through both the real treatment and a placebo, so each person acts as their own control — in 14 physically active, healthy men (average age ~24). Each man did a 7-day "loading phase" of either 20 g/day of creatine monohydrate or a matched maltodextrin placebo (split into four 5 g doses, 4 hours apart), separated by a 14-day washout to clear the creatine from their system before switching conditions.

The headline finding: after 7 days of creatine, men rated their sleep quality significantly higher than after placebo (a fairly large effect, Cohen's d = 0.81) and tended to head to bed earlier. They also performed better the next day — covering more total and peak distance on a repeated sprint test (5 m Shuttle Run Test), scoring higher on a cognitive attention task (Digit Cancellation Test), and reporting less muscle soreness on a general wellness questionnaire.

Here's the catch, and it's an important one: none of this showed up in the objective sleep data. Participants wore research-grade wrist actigraphy trackers (similar in concept to a Fitbit or Whoop, but used for sleep research) the entire week, and there was no measurable difference between creatine and placebo in how long it took to fall asleep, how efficiently they slept, or total sleep time. The only actigraphy difference was that creatine users got into bed slightly earlier. In other words, creatine didn't objectively change how people slept — it changed how good they felt about it, and how well they performed the next day. The authors are careful to frame this as a "perceptual" rather than physiological sleep benefit.

This tracks with a growing body of 2024-2025 research on creatine and brain energy metabolism. Separate trials have shown single high-dose creatine (0.2-0.35 g/kg) can blunt cognitive decline during actual sleep deprivation, and a 2024 meta-analysis of 16 RCTs found creatine reliably improves memory, attention, and processing speed, though not overall executive function. A 2025 NHANES population analysis also linked low dietary creatine intake to more self-reported trouble sleeping. Together, these suggest creatine's brain-energy effects are real, but this particular trial's sleep-quality improvement is best read as feeling more rested and recovered — not sleeping measurably differently — likely tied to reduced perceived fatigue and soreness rather than changed sleep architecture.

What This Means For You

This study reinforces standard sports-nutrition guidance rather than overturning it. The protocol used — 20 g/day split into four 5 g doses, 4 hours apart, for 5-7 days — is the classic "loading phase" recommended by the International Society of Sports Nutrition (ISSN) to saturate muscle creatine stores quickly. After loading, most people transition to a 3-5 g/day maintenance dose; you don't need to keep taking 20 g/day indefinitely.

For supplement shoppers: look for plain creatine monohydrate (the form used here and in the vast majority of research, often labeled "Creapure" for a quality-verified source) rather than pricier "advanced" forms (HCl, buffered, liquid) which lack comparable evidence of superiority. Take it with water; timing relative to workouts matters less than consistency.

Who benefits most? Physically active people already using creatine for strength/power gains can view this as a "bonus" — better next-day perceived recovery, sharper attention, and modestly reduced soreness, on top of the well-established performance boost in short, high-intensity efforts (sprints, repeated bouts, resistance training). If you're chronically sleep-deprived, other research suggests creatine's cognitive-protective effects may be even more pronounced.

Who should be cautious? People with kidney disease should consult a doctor before starting, since creatine increases the kidneys' filtration workload (though it's not damaging in healthy individuals). This study only examined healthy young men with already-good sleep hygiene — it says nothing about whether creatine helps people with insomnia or diagnosed sleep disorders, and shouldn't be marketed as a sleep aid. Creatine is inexpensive (often $15-25/month) and among the most evidence-backed supplements available, so the cost-benefit is favorable even if the sleep angle turns out to be modest.

Important Considerations

The biggest limitation is sample size: just 14 healthy young men. That's enough for a well-powered crossover design (each person served as their own control), but it's a narrow slice of the population — no women, no older adults, no one with existing sleep problems, poor sleep hygiene, or clinical conditions. Whether these findings generalize to women (whose creatine metabolism and hormonal context differ), athletes in heavy training blocks, or people with insomnia is unknown.

The "sleep quality" improvement was entirely self-reported via a 0-10 subjective scale — not confirmed by the objective wrist-actigraphy data, which showed no change in sleep latency, efficiency, or duration. This is a meaningful gap: it's possible participants simply felt better overall (less sore, sharper-headed) and that positive halo colored their sleep rating, rather than creatine directly improving sleep. The study's own authors state the effect appears "limited to perceptual improvements rather than broad physiological changes."

Other caveats: there was no pre-supplementation baseline performance test; the exact biological pathway (muscle vs. brain creatine uptake) wasn't measured directly; actigraphy can't capture sleep architecture (REM/deep sleep stages); and one puzzling result — significantly higher next-day muscle soreness (DOMS) at the 24-hour mark under creatine, despite lower general soreness on the wellness questionnaire — wasn't fully explained and deserves replication. As with any single small trial, treat this as suggestive rather than definitive, and be skeptical of any marketing claim that cites this study to sell creatine as a "sleep supplement."

Terms Explained

Creatine monohydrate (CrM)The most-researched, standard form of the creatine supplement, used to increase energy stores (phosphocreatine) in muscle and possibly brain tissue.

Loading phaseA short period (typically 5-7 days) of taking a higher creatine dose (~20 g/day) to quickly saturate the body's creatine stores, often followed by a lower daily maintenance dose.

Crossover trialA study design where every participant receives both the treatment and the placebo (in random order, separated by a washout period), so each person serves as their own comparison group.

Double-blind, placebo-controlledNeither participants nor researchers know who received the real supplement versus the inactive placebo, reducing bias in reported results.

ActigraphyA wrist-worn motion sensor used in sleep research to objectively estimate when someone fell asleep, woke up, and how efficiently they slept — similar to consumer sleep trackers.

Cohen's dA statistic describing how large an effect is, independent of sample size; roughly, 0.2 = small, 0.5 = medium, 0.8+ = large.

Phosphocreatine (PCr)The high-energy compound stored in muscle (and to a lesser extent, brain) that creatine supplementation increases, fueling rapid energy production during short, intense efforts.

Delayed Onset Muscle Soreness (DOMS)Muscle pain and stiffness that peaks roughly 24-72 hours after unaccustomed or intense exercise.

Washout periodA break between treatment phases in a crossover trial (14 days here) long enough for the first supplement's effects to clear before starting the next condition.

Technical Study Details

Study Design

RegistrationPan African Clinical Trials Registry (PACTR): PACTR202309597156293

Total Score

JADAD Quality Assessment

/ 5

評価詳細

Randomization

2 / 2

Is the study described as randomized?

Yes+1

Rationale: The article explicitly and repeatedly describes the study as "randomized" in the abstract, methods (experimental design), and results/discussion sections, including detailed description of the randomization procedure (block-randomization with rank-based allocation).

Is the method of randomization described and appropriate?

Yes+1

Rationale: The article explicitly describes the randomization method: a block-randomization procedure using the RAND() function in Microsoft Excel to generate random numbers, which were then used to rank and allocate participants to conditions. This is a computer-generated random number method, which is considered an appropriate randomization technique (analogous to using a random number table/generator), not an inappropriate method like alternation or date of birth/admission.</rationale> </invoke>

Blinding

2 / 2

Is the study described as double-blind?

Yes+1

Rationale: The article explicitly and repeatedly describes the study as "double-blind" in the abstract, methods (Experimental Design section), and discussion/limitations sections.

Is the method of blinding described and appropriate?

Yes+1

Rationale: The article explicitly describes a double-blind, placebo-controlled crossover design and details the blinding method: both CrM and placebo (corn-starch maltodextrin) were administered in identical powder form dissolved in water, in opaque unmarked containers handled by an independent (non-blinded) person, with participants instructed not to discuss taste to preserve blinding. This constitutes an appropriate and adequately described blinding method (similar appearance/preparation of active treatment vs. placebo, independent dispenser to maintain investigator blinding), satisfying the "yes" criteria for Jadad Q4.</rationale> </invoke>

Dropouts/Withdrawals

0 / 1

Is there a description of dropouts and withdrawals?

No0

Rationale: The article does not provide an explicit description of the number of withdrawals/dropouts and reasons for each treatment group. It only mentions that 14 participants were recruited specifically \"to avoid dropouts during the study,\" implying an anticipatory measure rather than a report of actual attrition. A \"Participants flow diagram\" (Figure 1) is referenced, which conventionally would show such information in a CONSORT-style crossover trial, but its actual content (numbers/reasons for withdrawal) is not included in the text provided, and no textual description of withdrawals/dropouts with reasons per group appears anywhere in the Methods, Results, or Discussion sections. Since the criteria require the number and reasons for withdrawals/dropouts to be stated for each treatment group, and this is not present in the available text, the answer is \"no.\""

Study Population

Sample Size14

Age RangeMean: 23.86 years

ConditionPhysically active, healthy men without pathological sleep disorders

Inclusion Criteria

Non-smokers
No pathological sleep disorders (Pittsburgh Sleep Quality Index < 5)
No insufficient sleep hygiene (Sleep Hygiene Index)
No injuries
Did not consume alcohol or foods rich in antioxidants/polyphenols
Did not use any medicine or dietary supplement during the experiment
Followed an omnivore diet without consuming creatine supplements
Participated in a variety of activities and/or sports for 2 or more days a week without a specific commitment or focus on sports competition

Interventions

Creatine monohydrate (CrM)

Treatment

Dose20 g/day (4 x 5 g servings)

Frequency4 servings/day, 4-hour interval between servings

Duration7 days (loading phase)

Routeoral

Placebo

Control

Dose20 g/day (4 x 5 g servings)

Frequency4 servings/day, 4-hour interval between servings

Duration7 days (loading phase)

Routeoral

Outcomes

Outcome	Type	Effect	p-value
Subjective Sleep Quality (SSQ)	Primary	-	p=0.009Significant
In-bed time	Primary	0.60	p=0.026Significant
Out-of-bed time	Primary	-	p=0.23
Sleep latency	Primary	-	p=0.35
Sleep efficiency	Primary	-	p=0.98
Total minutes in bed	Primary	-	p=0.6
Total sleep time	Primary	-	p=0.81
Hooper questionnaire - sleep item	Secondary	-	p=0.43
Hooper questionnaire - fatigue item	Secondary	-	p=0.55
Hooper questionnaire - stress item	Secondary	-	p=0.23
Hooper questionnaire - muscle soreness item	Secondary	-	p=0.046Significant
Hooper Index (total)	Secondary	-	p=0.63
Total distance (5mSRT)	Primary	0.88	<0.001Significant
Best distance (5mSRT)	Primary	0.76	<0.05Significant
Fatigue index (5mSRT)	Secondary	-	p=0.58
Performance decrement (5mSRT)	Secondary	-	p=0.16
Rating of Perceived Exertion	Secondary	-	p=0.42
Digit Cancellation Test score	Primary	-	p=0.013Significant
Feeling Scale	Secondary	-	p=0.32
Perceived Recovery Status	Secondary	-	<0.001
Delayed Onset Muscle Soreness	Secondary	-	<0.001

Conclusion

A short-term (7-day, 20 g/day) creatine monohydrate loading protocol improved subjective sleep quality (SSQ) during the supplementation phase, advanced in-bed time, reduced perceived muscle soreness (Hooper), enhanced cognitive performance (DCT), and increased physical output (total and best distance) during high-intensity intermittent exercise (5mSRT) compared to placebo. However, CrM did not significantly affect objective actigraphy-derived sleep parameters (latency, efficiency, total sleep time, out-of-bed time, total minutes in bed), fatigue index, performance decrement, RPE, feeling scale, or recovery markers (PRS, DOMS) up to 72 h post-exercise, aside from isolated differences at specific timepoints. The influence of creatine monohydrate on sleep appears limited to perceptual improvements rather than broad physiological changes, suggesting CrM may offer benefits beyond its traditional ergogenic role.

Limitations

Lack of a pre-supplementation (baseline) performance test
Precise biological pathways through which CrM affects outcomes are not fully understood
Actigraphy may not capture all dimensions of sleep quality, such as sleep architecture or subjective feelings of restfulness
Muscle and brain creatine levels were not evaluated before and after the supplementation period, so the magnitude of tissue creatine increase could not be determined
Effects of CrM may vary significantly between users, and findings from this population may not generalize to others